TORONTO, ON, CANADA (September 6, 2017)- Cyclica Inc. is pleased to announce that it has added Dr. Shane Climie as Vice President of Corporate Development.
Shane has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Shane has been a Principal at Popper and Company for 11 years where he has provided interim executive management services to early-stage biotechnology companies in the areas of diagnostics and drug discovery / drug development as well as support in the areas of business management, marketing strategy and technology or opportunity assessment. Prior to joining Popper and Company, Shane held several positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice President of Research Collaborations, and Vice President of Proteomics and Business Development. Dr. Climie was also co-founder, Vice President and Chief Technology Officer of MDS Ocata and was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. Prior to that, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. including Principal Scientist. Dr. Climie completed postdoctoral work at the University of California at San Francisco and received a Ph.D. in Medical Biophysics from the University of Toronto.
Naheed Kurji, Cyclica’s President and CEO, had this to say, “Shane is widely respected in the biotech space in North America, and has experience in drug discovery, proteomics, and corporate development. As Cyclica grows its global commercial footprint, Shane, with support from our Application Science team, will ensure that the needs of our clients are constantly met, and that we are gleaning strategic insights from the market to guide our future innovation efforts. We are thrilled to have Shane join our team, and I am looking forward to working closely with him to set the stage for Cyclica’s long-term success.”
Shane had this to say about his appointment, “I am excited to have an opportunity to become part of a creative and highly motivated team at Cyclica. The company is well positioned for growth through the application of its cloud-based Ligand Express technology that will enable partners to create significant value through a combination of structure- and knowledge-based proteome-wide screening, to identify and better characterize protein-drug interactions.”
— 30 —
Cyclica Inc. has developed, validated, patented and commercialized Ligand Express™, a cloud-based platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles. Accordingly, Ligand Express™ identifies significant protein targets using an innovative structure-based and drug-centric technology, leverages artificial intelligence to determine the drug’s effect on these targets, and visualizes the predicted drug-protein interactome using bioinformatics and systems biology. The platform provides a unique panoramic view of a small-molecule, by identifying on- and off-target interactions that may be expected, as well as those that are unanticipated. By understanding how a small-molecule drug will interact with all proteins in the body, Ligand Express™ augments scientific investigation by elucidating mechanism-of-action, prioritizing lead candidates, understanding side effects, as well as determining new uses for existing drugs. For more information please visit: www.cyclicarx.com